[1] |
CHENG S S, KEYES M J, LARSON M G, et al. Long-term outcomes in individuals with prolonged PR interval or first-degree atrioventricular block[J]. JAMA, 2009, 301(24):2571-2577. DOI: 10.1001/jama.2009.888.
|
[2] |
ARO A L, ANTTONEN O, KEROLA T, et al. Prognostic significance of prolonged PR interval in the general population[J]. Eur Heart J, 2014, 35(2):123-129. DOI: 10.1093/eurheartj/eht176.
|
[3] |
YARMOHAMMADI H, WAN E Y, BIVIANO A, et al. Prolonged PR interval and incidence of atrial fibrillation,heart failure admissions,and mortality in patients with implanted cardiac devices:a real-world survey[J]. Heart Rhythm O2, 2022, 22(3):171-179. DOI: 10.1016/j.hroo.2022.12.009.
|
[4] |
DU Z, XING L Y, LIN M, et al. Prevalence of first-degree atrioventricular block and the associated risk factors:a cross-sectional study in rural Northeast China[J]. BMC Cardiovasc Disord, 2019, 19(1):214. DOI: 10.1186/s12872-019-1202-4.
|
[5] |
SHAN R Q, NING Y, MA Y, et al. Prevalence and risk factors of atrioventricular block among 15 million Chinese health examination participants in 2018:a nation-wide cross-sectional study[J]. BMC Cardiovasc Disord, 2021, 21(1):289. DOI: 10.1186/s12872-021-02105-3.
|
[6] |
|
[7] |
|
[8] |
|
[9] |
|
[10] |
|
[11] |
中国超重/肥胖医学营养治疗专家共识编写委员会. 中国超重/肥胖医学营养治疗专家共识(2016年版)[J]. 糖尿病天地(临床),2016,10(9):395-398.
|
[12] |
王增武,刘静,李建军,等. 中国血脂管理指南(2023年)[J]. 中国循环杂志,2023,38(3):237-271.
|
[13] |
|
[14] |
PERLMAN L V, OSTRANDER L D Jr, KELLER J B, et al. An epidemiologic study of first degree atrioventricular block in Tecumseh,Michigan[J]. Chest, 1971, 59(1):40-46. DOI: 10.1378/chest.59.1.40.
|
[15] |
VILLA M, CERDA-OPAZO P, JIMENEZ-GALLEGOS D, et al. Pro-fibrotic effect of oxidized LDL in cardiac myofibroblasts[J]. Biochem Biophys Res Commun, 2020, 524(3):696-701. DOI: 10.1016/j.bbrc.2020.01.156.
|
[16] |
FROSTEGÅRD J. Immunity,atherosclerosis and cardiovascular disease[J]. BMC Med, 2013, 11:117. DOI: 10.1186/1741-7015-11-117.
|
[17] |
|
[18] |
LAZZERINI P E, ACAMPA M, CUPELLI M, et al. Unravelling atrioventricular block risk in inflammatory diseases:systemic inflammation acutely delays atrioventricular conduction via a cytokine-mediated inhibition of Connexin43 expression[J]. J Am Heart Assoc, 2021, 10(21):e022095. DOI: 10.1161/JAHA.121.022095.
|
[19] |
|
[20] |
YANAI H, ADACHI H, HAKOSHIMA M, et al. Molecular biological and clinical understanding of the pathophysiology and treatments of hyperuricemia and its association with metabolic syndrome,cardiovascular diseases and chronic kidney disease[J]. Int J Mol Sci, 2021, 22(17):9221. DOI: 10.3390/ijms22179221.
|
[21] |
HARVEY A, MONTEZANO A C, LOPES R A, et al. Vascular fibrosis in aging and hypertension:molecular mechanisms and clinical implications[J]. Can J Cardiol, 2016, 32(5):659-668. DOI: 10.1016/j.cjca.2016.02.070.
|
[22] |
ARO A L. First-degree atrioventricular block:risk marker or innocent finding?[J]. Heart, 2016, 102(9):655-656. DOI: 10.1136/heartjnl-2015-309256.
|
[23] |
TADROS R, TON A T, FISET C, et al. Sex differences in cardiac electrophysiology and clinical arrhythmias:epidemiology,therapeutics,and mechanisms[J]. Can J Cardiol, 2014, 30(7):783-792. DOI: 10.1016/j.cjca.2014.03.032.
|
[24] |
CUSPIDI C, CIULLA M, ZANCHETTI A. Hypertensive myocardial fibrosis[J]. Nephrol Dial Transplant, 2006, 21(1):20-23. DOI: 10.1093/ndt/gfi237.
|
[25] |
SALVADOR D B J R, GAMBA M R, GONZALEZ-JARAMILLO N, et al. Diabetes and myocardial fibrosis:a systematic review and meta-analysis[J]. JACC Cardiovasc Imaging, 2022, 15(5):796-808. DOI: 10.1016/j.jcmg.2021.12.008.
|
[26] |
HENNING R J. Type-2 diabetes mellitus and cardiovascular disease[J]. Future Cardiol, 2018, 14(6):491-509. DOI: 10.2217/fca-2018-0045.
|